FRA:ANU1 Archives - The Canadian Business Quarterly

FRA:ANU1

Featured image XORTX - Dr. Allen Davidoff, President and CEO

XORTX Therapeutics (FRA:ANU1 | CSE:XRX | OTCQB:XRTXF): Redefining kidney disease treatment

August 18, 2020 / The Canadian Business Quarterly

A publicly-listed biopharmaceutical company with three clinically advanced products in development, XORTX Therapeutics’ focus is on developing drugs for kidney disease treatment, an area where there is a large unmet

Hinton Scaffold Solutions: Utilizing innovate technologies to create safer worksites

Alberta Veterinary Laboratories / Solvet: Supporting Canada’s food

Sodexo Canada: The global leader who believes the difference a day makes

Barclay Restorations DKI: The longest running insurance restoration company in Greater Vancouver

CDW Canada: Helping small businesses use IT security to prepare, defend, and respond

Stamped Engineering Corporation: High quality, fit for purpose engineering services

Alpine Building Maintenance: Customized cleaning solutions

Case Design/Remodeling Halifax: Flawless design and execution

Washed up elites need to stop lecturing the people

The political timing of Finland’s admission into NATO

How to manage the stress of making the right business decisions

Reclaiming Canada’s key service export: Tourism

Concerning signs for Canada’s construction sector in 2023

Strengthening your organization through sustainability & ESG

55% of provincial healthcare budgets will be for seniors by 2030

Spymasters, conspiracies, the PRC, & Dong Jingwei

FRA:ANU1

XORTX Therapeutics (FRA:ANU1 | CSE:XRX | OTCQB:XRTXF): Redefining kidney disease treatment

Subscribe

Subscribe

© 2023 The Canadian Business Quarterly. All rights reserved. A division of Romulus Rising Pty Ltd, an Australian media company (www.RomulusRising.com).